The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2′-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes

Biochemical Pharmacology

Volumn 82, Issue 5, 2011, Pages 441-452

  Vande Voorde, Johan ^a   Liekens, Sandra ^a   McGuigan, Christopher ^b   Murziani, Paola G S ^b   Slusarczyk, Magdalena ^b   Balzarini, Jan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

5 Fluoro 2 deoxyuridine (5 FdUrd); Cancer; Mycoplasma; Nucleoside analogues; Phosphoramidate prodrugs; Thymidine phosphorylase

Indexed keywords

FLOXURIDINE; NUC 3073; PHOSPHORAMIDIC ACID DERIVATIVE; PRODRUG; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; URIDINE PHOSPHORYLASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION; CYTOSTASIS; DRUG DEGRADATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA L 1210; LYMPHOCYTE; MOUSE; MYCOPLASMA; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ENZYME ACTIVATION; FLOXURIDINE; HUMANS; LEUKEMIA L1210; MICE; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHORYLATION; PRODRUGS; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE; URIDINE PHOSPHORYLASE;

EID: 79960929739     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.05.024     Document Type: Article

References (46)

1. Hatse S, De Clercq E, Balzarini J. Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation. Biochem Pharmacol 1999;58:539-55. (Pubitemid 29296875)
2. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 2002;3:415-24. (Pubitemid 36958272)
3. de Bruin M, van Capel T, Smid K, van der Born K, Fukushima M, Hoekman K, et al. Role of platelet derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity and potential role of deoxyribose-1-phosphate. Nucleosides Nucleotides Nucleic Acids 2004;23:1485-90. (Pubitemid 39625948)
4. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998;55:1091-7. (Pubitemid 28167730)
5. Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005;27:23-44. (Pubitemid 40347299)
6. Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Renee N, et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994;30A:1517-22. (Pubitemid 24343014)
7. Tanaka F, Fukuse T, Wada H, Fukushima M. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents. Curr Pharm Biotechnol 2000;1:137-64.
8. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8. (Pubitemid 37328853)
9. Mehellou Y, Balzarini J, McGuigan C. Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells. ChemMedChem 2009;4:1779-91.
10. Hecker SJ, Erion MD. Prodrugs of phosphates and phosphonates. J Med Chem 2008;51:2328-45. (Pubitemid 351628494)
11. Harris SA, McGuigan C, Andrei G, Snoeck R, De Clercq E, Balzarini J. Synthesis and antiviral evaluation of phosphoramidate derivatives of (E)-5-(2-bromovinyl)-2′-deoxyuridine. Antivir Chem Chemother 2001;12:293-300. (Pubitemid 34168777)
12. Congiatu C, Brancale A, Mason MD, Jiang WG, McGuigan C. Novel potential anticancer naphthyl phosphoramidates of BVdU: separation of diastereoisomers and assignment of the absolute configuration of the phosphorus center. J Med Chem 2006;49:452-5. (Pubitemid 43157476)
13. Derudas M, Carta D, Brancale A, Vanpouille C, Lisco A, Margolis L, et al. The application of phosphoramidate protide technology to acyclovir confers anti- HIV inhibition. J Med Chem 2009;52:5520-30.
14. Razin S, Yogev D, Naot Y. Molecular biology and pathogenicity of mycoplasmas. Microbiol Mol Biol Rev 1998;62:1094-156. (Pubitemid 28558294)
15. Huang S, Li JY, Wu J, Meng L, Shou CC. Mycoplasma infections and different human carcinomas. World J Gastroenterol 2001;7:266-9. (Pubitemid 32377482)
16. Pehlivan M, Itirli G, Onay H, Bulut H, Koyuncuoglu M, Pehlivan S. Does Mycoplasma sp. play role in small cell lung cancer? Lung Cancer 2004;45:129-30. (Pubitemid 38757842)
17. Pehlivan M, Pehlivan S, Onay H, Koyuncuoglu M, Kirkali Z. Can mycoplasmamediated oncogenesis be responsible for formation of conventional renal cell carcinoma? Urology 2005;65:411-4. (Pubitemid 40248052)
18. Chan PJ, Seraj IM, Kalugdan TH, King A. Prevalence of mycoplasma conserved DNA in malignant ovarian cancer detected using sensitive PCR-ELISA. Gynecol Oncol 1996;63:258-60. (Pubitemid 26398609)
19. Sasaki H, Igaki H, Ishizuka T, Kogoma Y, Sugimura T, Terada M. Presence of Streptococcus DNA sequence in surgical specimens of gastric cancer. Jpn J Cancer Res 1995;86:791-4.
20. Yang H, Qu L, Ma H, Chen L, Liu W, Liu C, et al. Mycoplasma hyorhinis infection in gastric carcinoma and its effects on the malignant phenotypes of gastric cancer cells. BMC Gastroenterol 2010;10:132.
21. Kidder M, Chan PJ, Seraj IM, Patton WC, King A. Assessment of archived paraffin-embedded cervical condyloma tissues for mycoplasma-conserved DNA using sensitive PCR-ELISA. Gynecol Oncol 1998;71:254-7. (Pubitemid 28550809)
22. Razin S. The mycoplasmas. Microbiol Rev 1978;42:414-70. (Pubitemid 8378881)
23. Charron J, Langelier Y. Analysis of deoxycytidine (dC) deaminase activity in herpes simplex virus-infected or HSV TK-transformed cells: association with mycoplasma contamination but not with virus infection. J Gen Virol 1981;57:245-50. (Pubitemid 12180319)
24. Neale GA, Mitchell A, Finch LR. Enzymes of pyrimidine deoxyribonucleotide metabolism in Mycoplasma mycoides subsp. mycoides. J Bacteriol 1983;156:1001-5. (Pubitemid 14216320)
25. Tham TN, Ferris S, Kovacic R, Montagnier L, Blanchard A. Identification of Mycoplasma pirum genes involved in the salvage pathways for nucleosides. J Bacteriol 1993;175:5281-5. (Pubitemid 23232595)
26. Sinigaglia F, Talmadge KW. Inhibition of [3H]thymidine incorporation by Mycoplasma arginini-infected cells due to enzymatic cleavage of the nucleoside. Eur J Immunol 1985;15:692-6. (Pubitemid 15028942)
27. Bronckaers A, Balzarini J, Liekens S. The cytostatic activity of pyrimidine nucleosides is strongly modulated by Mycoplasma hyorhinis infection: implications for cancer therapy. Biochem Pharmacol 2008;76:188-97.
28. Jetté L, Bissoon-Haqqani S, Le François B, Maroun JA, Birnboim HC. Resistance of colorectal cancer cells to 5-FUdR and 5-FU caused by Mycoplasma infection. Anticancer Res 2008;28:2175-80.
29. Liekens S, Bronckaers A, Balzarini J. Improvement of purine and pyrimidine antimetabolite-based anticancer treatment by selective suppression of mycoplasma- encoded catabolic enzymes. Lancet Oncol 2009;10:628-35.
30. McGuigan C, Pathirana RN, Balzarini J, De Clercq E. Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT. J Med Chem 1993;36:1048-52. (Pubitemid 23143618)
31. McGuigan C, Cahard D, Sheeka HM, De Clercq E, Balzarini J. Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite. J Med Chem 1996;39:1748-53. (Pubitemid 26124246)
32. McGuigan C, Tsang HW, Cahard D, Turner K, Velazquez S, Salgado A, et al. Phosphoramidate derivatives of d4T as inhibitors of HIV: the effect of amino acid variation. Antiviral Res 1997;35:195-204. (Pubitemid 27351420)
33. Balzarini J, De Clercq E, Torrence PF, Mertes MP, Park JS, Schmidt CL, et al. Role of thymidine kinase in the inhibitory activity of 5-substituted- 2′-deoxyuridines on the growth of human and murine tumor cell lines. Biochem Pharmacol 1982;31:1089-95. (Pubitemid 12147953)
34. Balzarini J, De Clercq E. Strategies for the measurement of the inhibitory effects of thymidine analogs on the activity of thymidylate synthase in intact murine leukemia L1210 cells. Biochim Biophys Acta 1984;785:36-45. (Pubitemid 14194736)
35. Mehellou Y, Valente R, Mottram H, Walsby E, Mills KI, Balzarini J, et al. Phosphoramidates of 2′-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. Bioorg Med Chem 2010;18:2439-46.
36. Agarwal RP, Han T, Fernandez M. Collateral resistance of a dideoxycytidine-resistant cell line to 5-fluoro-2′-deoxyuridine. Biochem Biophys Res Commun 1999;262:657-60. (Pubitemid 29443714)
37. Murakami Y, Kazuno H, Emura T, Tsujimoto H, Suzuki N, Fukushima M. Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol 2000;17:277-83.
38. Kosaka T, Usami K, Ueshige N, Sugaya J, Nakano Y, Takashima S. Effects of thymidine phosphorylase levels in cancer, background mucosa, and regional lymph nodes on survival of advanced gastric cancer patients receiving post-operative fluoropyrimidine therapy. Oncol Rep 2004;12:1279-86.
39. Zhang ZG, Harstrick A, Rustum YM. Mechanisms of resistance to fluoropyrimidines. Semin Oncol 1992;19(2 Suppl. 3):4-9.
40. Sobrero AF, Moir RD, Bertino JR, Handschumacher RE. Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2′-deoxyuridine in the HCT-8 human carcinoma line. Cancer Res 1985;45: 3155-60. (Pubitemid 15007188)
41. Kamoshida S, Shiogama K, Shimomura R, Inada K, Sakurai Y, Ochiai M, et al. Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer. Oncol Rep 2005;14:1223-30.
42. Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, et al. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology 2006;70:366-77. (Pubitemid 46066130)
43. Koopman M, Venderbosch S, Nagtegaal ID, van Krieken JH, Punt CJ. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? Eur J Cancer 2009;45:1935-49.
44. Ciccolini J, Evrard A, Cuq P. Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story. Curr Med Chem Anticancer Agents 2004;4:71-81.
45. Bronckaers A, Gago F, Balzarini J, Liekens S. The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev 2009;29:903-53.
46. Lee WA, He GX, Eisenberg E, Cihlar T, Swaminathan S, Mulato A, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother 2005;49:1898-906. (Pubitemid 40631605)